reason report
updat model margetuximab sophia readout pt
bottom line updat model follow
op announc last week posit top-lin result
phase sophia studi zlab-partn margetuximab fc-
engin antibodi metastat breast cancer
mbc link recal zlab previous acquir full greater
china commerci right three program includ
margetuximab bispecif
undisclos preclin program trident tri-specif
platform link believ posit breast cancer readout could
also read-through sentiment margetuximab gastric cancer
opportun well repres sizabl commerci opportun
china updat price target reflect probabl success po
margetuximab mbc vs previous
gastric cancer vs previous continu
view zlab well-posit benefit china rapidli grow
emerg biopharma market strong manag team
extens experi in-depth knowledg evolv drug
develop commerci landscap china recal zlab
china-bas global biopharmaceut compani target area
unmet medic need china global market in-
licens intern discoveri effort oncolog infecti diseas
autoimmun diseas zlab multipl shot goal broad
pipelin asset in-licens gsk/tsro nr op
oncolog asset niraparib optun margetuximab
omadacyclin infecti diseas addit zlab
earli stage in-hous effort repres potenti sourc long-
term upsid investor continu view compani favor
strong experienc manag team posit execut
reiter op price target
mileston catalyst includ niraparib china phase
data recurr platinum-sensit ovarian cancer mainten
niraparib prima readout potenti niraparib china
nda approv launch potenti optun china approv
trial waiver launch sophia data present
partner phase data
initi dose phase global registr trial
infecti diseas advanc announc intern
multipl dr tgr
year price history/av daili volume mil zlab
compani inform svb leerink llc research
revenu present million ep
pleas refer page import disclosur price chart analyst certif
rate zlab outperform zai lab china-bas global biopharmaceut compani
target area unmet medic need china global market in-licens
intern discoveri effort oncolog infecti diseas autoimmun diseas
view zlab well-posit benefit china rapidli grow emerg biopharma market
strong manag team extens experi in-depth knowledg
evolv drug develop commerci landscap china zlab multipl shot
goal broad pipelin asset in-licens tsro
etc includ late stage asset niraparib zejula oncolog
bemarituzumab oncolog optun oncolog margetuximab oncolog
omadacyclin infecti diseas addit zlab earli stage in-hous
effort focus immunotherapi target approach oncolog
repres potenti sourc long-term upsid investor
price target zlab base blend dcf analysi revenu
multipl analysi assign valu probability-weight opportun niraparib ovarian
cancer probabl success ovarian cancer probabl success
ovarian cancer probabl success tripl neg breast cancer probabl
success brca breast cancer probabl success assign valu probability-
weight opportun omadacyclin absssi acute-bacteri skin skin-structur
infect probabl success cabp commun acquir bacteri pneumonia
probabl success assign valu probability-weight opportun brivanib
hepatocellular carcinoma probabl success assign valu probability-
weight opportun optun glioblastoma probabl success assign valu
probability-weight opportun gastric cancer probabl success
assign valu probability-weight opportun margetuximab breast cancer
probabl success gastric cancer probabl success assign valu
probability-weight opportun baumannii probabl success
assign valu probability-weight opportun tumor-tr field glioblastoma
probabl success earlier stage develop program repres potenti sourc long-
term upsid valuat use discount rate termin growth rate
zlab pipelin program face clinic regulatori develop risk well commerci
intellectu properti risk zlab also face execut risk financi risk zlab may
addit financ need turn cash flow posit
zlab mm except per share
product sale minu royalti lessor p/w
licens collabor revenu
chang fair valu warrent
share loss equiti method invest
net incom tax
zlab bs cf mm
sec file svb leerink estim
chang
effect exchang rate cash
sec file svb leerink estim
approv hong
zlab pipelin upcom event
mainland china approv base
gastric gastro-esophag junction cancer
hepatocellular carcinoma combin
approv us eu
approv us eu
mesothelioma stellar trial concomit pemetrex cisplatin
nsclc lunar trial concurr standard therapi
pancreat panova trial concomit gemcitabin gemcitabin nab-
pancreat panova trial concomit gemcitabin nab-
approal trial waiver
applic submit fda approv
malign pleural mesothelioma
bioequival pk bridg studi
line breast cancer
tnbc china
brca china
